FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2161604858> ?p ?o ?g. }

• W2161604858 endingPage "752" @default.
• W2161604858 startingPage "743" @default.
• W2161604858 abstract "BackgroundBisphosphonates are the standard of care for reducing the risk of skeletal-related events in patients with bone lesions from multiple myeloma. The MRC Myeloma IX study was designed to compare the effects of zoledronic acid versus clodronic acid in newly diagnosed patients with multiple myeloma. Here, we report the secondary outcomes relating to skeletal events.MethodsPatients (≥18 years) with newly diagnosed multiple myeloma were enrolled from 120 centres in the UK and received intensive or non-intensive antimyeloma treatment. A computer-generated randomisation sequence was used to allocate patients in a 1:1 ratio, through an automated telephone service to intravenous zoledronic acid (4 mg every 21–28 days) or oral clodronic acid (1600 mg/day), and the drugs were continued at least until disease progression. No investigators, staff, or patients were masked to treatment allocation. The primary endpoints—overall survival, progression-free survival, and overall response rate—and adverse events have been reported previously. We assessed between-group differences with Cox proportional hazards models for time to first skeletal-related event and incidence of skeletal-related events. These were defined as fractures, spinal cord compression, radiation or surgery to bone, and new osteolytic lesions. Data were analysed until disease progression. Analyses were by intention to treat. This trial is registered, number ISRCTN68454111.Findings1960 patients were randomly assigned and analysed—981 in the zoledronic acid group and 979 in the clodronic acid group. This trial is fully enrolled, and follow-up continues. At a median follow-up of 3·7 years (IQR 2·9–4·7), patients in the zoledronic acid group had a lower incidence of skeletal-related events than did those in the clodronic acid group (265 [27%] vs 346 [35%], respectively; hazard ratio 0·74, 95% CI 0·62–0·87; p=0·0004). Zoledronic acid was also associated with a lower risk of any skeletal-related event in the subsets of patients with (233 [35%] of 668 vs 292 [43%] of 682 with clodronic acid; 0·77, 0·65–0·92; p=0·0038) and without bone lesions at baseline (29 [10%] of 302 vs 48 [17%] of 276 with clodronic acid; 0·53, 0·33–0·84; p=0·0068). Fewer patients in the zoledronic acid group had vertebral fractures than did those in the clodronic acid group (50 [5%] in the zoledronic acid group vs 88 [9%] in the clodronic acid group; p=0·0008), other fractures (45 [5%] vs 66 [7%]; p=0·04), and new osteolytic lesions (46 [5%] vs 95 [10%]; p<0·0001).InterpretationThe results of this study support the early use of zoledronic acid rather than clodronic acid in patients with newly diagnosed multiple myeloma for the prevention of skeletal-related events, irrespective of bone disease status at baseline.FundingMedical Research Council (London, UK), Novartis, Schering Health Care, Chugai, Pharmion, Celgene, and Ortho Biotech." @default.
• W2161604858 created "2016-06-24" @default.
• W2161604858 creator A5003687947 @default.
• W2161604858 creator A5009505468 @default.
• W2161604858 creator A5011400814 @default.
• W2161604858 creator A5016246851 @default.
• W2161604858 creator A5017165070 @default.
• W2161604858 creator A5017554622 @default.
• W2161604858 creator A5018664633 @default.
• W2161604858 creator A5031533686 @default.
• W2161604858 creator A5032055781 @default.
• W2161604858 creator A5034560778 @default.
• W2161604858 creator A5034702019 @default.
• W2161604858 creator A5038580329 @default.
• W2161604858 creator A5063301766 @default.
• W2161604858 creator A5065378097 @default.
• W2161604858 creator A5069451301 @default.
• W2161604858 creator A5070032224 @default.
• W2161604858 creator A5075026758 @default.
• W2161604858 creator A5081247376 @default.
• W2161604858 creator A5085134973 @default.
• W2161604858 date "2011-08-01" @default.
• W2161604858 modified "2023-09-30" @default.
• W2161604858 title "Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial" @default.
• W2161604858 cites W1530002712 @default.
• W2161604858 cites W1932993947 @default.
• W2161604858 cites W1974493848 @default.
• W2161604858 cites W1986705681 @default.
• W2161604858 cites W2025707250 @default.
• W2161604858 cites W2035237112 @default.
• W2161604858 cites W2040925557 @default.
• W2161604858 cites W2045031638 @default.
• W2161604858 cites W2048709843 @default.
• W2161604858 cites W2056684547 @default.
• W2161604858 cites W2066342798 @default.
• W2161604858 cites W2077941564 @default.
• W2161604858 cites W2097878023 @default.
• W2161604858 cites W2103011422 @default.
• W2161604858 cites W2104923745 @default.
• W2161604858 cites W2105289281 @default.
• W2161604858 cites W2115871403 @default.
• W2161604858 cites W2119486128 @default.
• W2161604858 cites W2120929463 @default.
• W2161604858 cites W2123171945 @default.
• W2161604858 cites W2134071321 @default.
• W2161604858 cites W2135156120 @default.
• W2161604858 cites W2141884093 @default.
• W2161604858 cites W2142234592 @default.
• W2161604858 cites W2143254775 @default.
• W2161604858 cites W2161962336 @default.
• W2161604858 cites W2165326697 @default.
• W2161604858 cites W2550250512 @default.
• W2161604858 doi "https://doi.org/10.1016/s1470-2045(11)70157-7" @default.
• W2161604858 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3148431" @default.
• W2161604858 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21771568" @default.
• W2161604858 hasPublicationYear "2011" @default.
• W2161604858 type Work @default.
• W2161604858 sameAs 2161604858 @default.
• W2161604858 citedByCount "144" @default.
• W2161604858 countsByYear W21616048582012 @default.
• W2161604858 countsByYear W21616048582013 @default.
• W2161604858 countsByYear W21616048582014 @default.
• W2161604858 countsByYear W21616048582015 @default.
• W2161604858 countsByYear W21616048582016 @default.
• W2161604858 countsByYear W21616048582017 @default.
• W2161604858 countsByYear W21616048582018 @default.
• W2161604858 countsByYear W21616048582019 @default.
• W2161604858 countsByYear W21616048582020 @default.
• W2161604858 countsByYear W21616048582021 @default.
• W2161604858 countsByYear W21616048582022 @default.
• W2161604858 countsByYear W21616048582023 @default.
• W2161604858 crossrefType "journal-article" @default.
• W2161604858 hasAuthorship W2161604858A5003687947 @default.
• W2161604858 hasAuthorship W2161604858A5009505468 @default.
• W2161604858 hasAuthorship W2161604858A5011400814 @default.
• W2161604858 hasAuthorship W2161604858A5016246851 @default.
• W2161604858 hasAuthorship W2161604858A5017165070 @default.
• W2161604858 hasAuthorship W2161604858A5017554622 @default.
• W2161604858 hasAuthorship W2161604858A5018664633 @default.
• W2161604858 hasAuthorship W2161604858A5031533686 @default.
• W2161604858 hasAuthorship W2161604858A5032055781 @default.
• W2161604858 hasAuthorship W2161604858A5034560778 @default.
• W2161604858 hasAuthorship W2161604858A5034702019 @default.
• W2161604858 hasAuthorship W2161604858A5038580329 @default.
• W2161604858 hasAuthorship W2161604858A5063301766 @default.
• W2161604858 hasAuthorship W2161604858A5065378097 @default.
• W2161604858 hasAuthorship W2161604858A5069451301 @default.
• W2161604858 hasAuthorship W2161604858A5070032224 @default.
• W2161604858 hasAuthorship W2161604858A5075026758 @default.
• W2161604858 hasAuthorship W2161604858A5081247376 @default.
• W2161604858 hasAuthorship W2161604858A5085134973 @default.
• W2161604858 hasBestOaLocation W21616048581 @default.
• W2161604858 hasConcept C120665830 @default.
• W2161604858 hasConcept C121332964 @default.
• W2161604858 hasConcept C126322002 @default.
• W2161604858 hasConcept C141071460 @default.
• W2161604858 hasConcept C143998085 @default.
• W2161604858 hasConcept C168563851 @default.

• next